Home | About the eMC | Help | Mobile
eMC - trusted, up to date and comprehensive information about medicines
Link to eMC medicine guides website
eMC homepage
Advanced search
Get Medicines Compendium UK app here

Roche Products Limited
Hexagon Place, 6 Falcon Way, Shire Park, Welwyn Garden City, Hertfordshire, AL7 1TW
Telephone: +44 (0)1707 366 000
Fax: +44 (0)1707 338 297
WWW: http://www.rocheuk.com
Medical Information Direct Line: +44 (0)800 328 1629
Medical Information e-mail: medinfo.uk@roche.com
Customer Care direct line: +44 (0)800 731 5711
Medical Information Fax: +44 (0)1707 384555

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?
Patient Information Leaflet last updated on the eMC: 14/11/2011
PIL Tamiflu 12mg/ml powder for oral suspension

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 14/11/2011 and displayed until Current
Reasons for adding or updating:
  • Change to date of revision
  • Change to side-effects
Updated on 28/02/2011 and displayed until 14/11/2011
Reasons for adding or updating:
  • Change to side-effects
Updated on 18/01/2011 and displayed until 28/02/2011
Reasons for adding or updating:
  • Change to date of revision
  • Removed by Datapharm
Updated on 17/12/2010 and displayed until 18/01/2011
Reasons for adding or updating:
  • Change/addition of instructions for reconstitution and/ or administration
  • Change to side-effects
Updated on 16/07/2010 and displayed until 17/12/2010
Reasons for adding or updating:
  • Change to how the medicine works
Updated on 23/03/2010 and displayed until 16/07/2010
Reasons for adding or updating:
  • Change to drug interactions
Updated on 11/11/2009 and displayed until 23/03/2010
Reasons for adding or updating:
  • Change/addition of instructions for reconstitution and/ or administration
  • PIL Retired pending re-submission
Updated on 15/09/2009 and displayed until 11/11/2009
Reasons for adding or updating:
  • Change to side-effects
  • Change to information about pregnancy or lactation
  • PIL Retired pending re-submission
Updated on 17/02/2009 and displayed until 15/09/2009
Reasons for adding or updating:
  • Change to dosage and administration
Updated on 11/12/2008 and displayed until 17/02/2009
Reasons for adding or updating:
  • Change to side-effects
Updated on 16/10/2008 and displayed until 11/12/2008
Reasons for adding or updating:
  • Change to side-effects
Updated on 07/12/2007 and displayed until 16/10/2008
Reasons for adding or updating:
  • Change to warnings or special precautions for use
Updated on 06/11/2007 and displayed until 07/12/2007
Reasons for adding or updating:
  • Change to warnings or special precautions for use
Updated on 12/09/2007 and displayed until 06/11/2007
Reasons for adding or updating:
  • Change to warnings or special precautions for use
  • Change to information about driving or using machinery
  • Change to side-effects
  • Change to storage instructions
  • Change to Further Information section
Updated on 13/04/2007 and displayed until 12/09/2007
Reasons for adding or updating:
  • Change to side-effects
  • Change to Further Information section
  • Change to date of revision
Updated on 28/02/2006 and displayed until 13/04/2007
Reasons for adding or updating:
  • Change to Marketing Authorisation Holder
  • Change to date of revision
  • Change to how to administer the medicine
Updated on 31/01/2005 and displayed until 28/02/2006
Reasons for adding or updating:
  • Change to Further Information section
Updated on 04/03/2004 and displayed until 31/01/2005
Reasons for adding or updating:
  • Update to PIL
Updated on 22/10/2002 and displayed until 04/03/2004
Reasons for adding or updating:
  • New PIL for new product

Active Ingredients/Generics

 
  oseltamivir phosphate